Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (444)

« Back to Publications

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.

Wu X. et al, (2019), Prostate, 79, 1079 - 1089

Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

Assel M. et al, (2019), Eur Urol Focus, 5, 561 - 567

16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Hugosson J. et al, (2019), Eur Urol, 76, 43 - 51

The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition.

Smith Byrne K. et al, (2019), Ann Oncol, 30, 983 - 989

Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.

Preston MA. et al, (2019), Eur Urol, 75, 399 - 407

Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7.

Vickers AJ. et al, (2019), Eur Urol, 75

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.

Bancroft EK. et al, (2019), BJU Int, 123, 284 - 292

Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.

Thorek DLJ. et al, (2019), Clin Cancer Res, 25, 881 - 891

inary extracellular vesicle microRNA biomarker discovery pipeline; from automated extracellular vesicle enrichment by acoustic trapping to microRNA sequencing.

Ku A. et al, (2019), PLoS One, 14

Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function.

Srinivasan S. et al, (2019), Clin Chem, 65, e1 - e9

Clinical Chemistry's Special Issue on Men's Health.

Park JY. et al, (2019), Clin Chem, 65, 1 - 3

Perspective on Prostate Cancer Screening.

Carlsson SV. and Lilja H., (2019), Clin Chem, 65, 24 - 27

Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.

Li W. et al, (2018), Eur Urol, 74, 710 - 719

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.

Kallio HML. et al, (2018), Br J Cancer, 119, 347 - 356

Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.

Frånlund M. et al, (2018), Scand J Urol, 52, 256 - 262

Load More

1
2
3
4
5
6
7
...
»